Do you want to read an article? Please log in or register.
LBA2: SARC041: Abemaciclib demonstrates first positive phase III trial results in dedifferentiated liposarcoma
Sarcoma
CHICAGO 2026
Related content
Lung, Respiratory and Thoracic Cancer
Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 "DICIPLE" Phase III trial
J Thorac Oncol
Zalcman G, Madroszyk A, Guenzi E, Dayen C, Molinier O, Egenod T, Poté N, Debieuvre D, Beaucaire-Danel S, Dixmier A, Pichon E, Galland-Girodet S, Giroux-Leprieur E, Cloarec N, Cadranel J, Otto J, Romand P, Favier L, Martinez S, Mascaux C, Odier L, Cortot A, Audigier-Valette C, Langlais A, Amour E, Morin F, Antoine M, Gounant V, Westeel V, Toffart AC
doi: 10.1016/j.jtho.2026.103609
COMMENTED
Breast Cancer
Breastfeeding After Hormone Receptor-Positive Breast Cancer: Results From the POSITIVE Trial
★ 2
Recommended and commented by
Dr Andreas Müller, Faculty Member
J Clin Oncol
Peccatori FA, Niman SM, Partridge AH, Ruggeri M, Colleoni M, Saura C, Shimizu C, Satersdal AB, Kroep JR, Gelmon K, Amant F, Mailliez A, Moore HCF, Ruiz-Borrego M, Walshe JM, Borges VF, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Klar NJ, Ferreiro T, El-Abed S, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O, Azim HA Jr, International Breast Cancer Study Group and the POSITIVE Trial Collaborators
doi: 10.1200/JCO-24-02697
Genitourinary Cancer
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial
Ann Oncol
Choueiri TK, Albigès L, McDermott DF, Hammers HJ, Escudier B, Burotto M, Plimack ER, Porta C, George S, Powles T, Donskov F, Atkins MB, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Castellano D, Grünwald V, Tomita Y, Rini BI, Jiang R, van Kooten Losio M, Lee CW, Tannir NM, Motzer RJ
doi: 10.1016/j.annonc.2026.02.017
RECOMMENDED
Breast Cancer
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer: Updated Efficacy Results from the phase 3 EMBER-3 trial
★ 2
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Ann Oncol
Jhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, Saura C, O'Shaughnessy J, Harbeck N, Carey LA, Curigliano G, Watanabe J, Lim E, Huang J, Qingyuan Z, Llombart-Cussac A, Huang C, Desai B, Limay Y, Wang XA, Cao S, Bidard FC
doi: 10.1016/j.annonc.2025.11.018
COMMENTED
Breast Cancer
Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial
★ 2
Recommended and commented by
Dr Andreas Müller, Faculty Member
J Clin Oncol
Gao HF, Ye GL, Lin Y, Huang Q, Dong J, Cao Y, Zhao YX, Chen QJ, Ma SH, Ouyang J, Ye JH, Yang HW, Zhang YQ, Zhang YC, Zhang GL, Li W, Zhang Y, Wu ZY, Lin YY, Zhu T, Zhang LL, Yang CQ, Yang M, Peng H, Chen B, Chen YT, Ji F, Cheng MY, Li JQ, Jiang Z, Wang K
doi: 10.1200/JCO-25-02176
Gynecologic Cancer
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial
J Clin Oncol
Harter P, Marmé F, Redondo A, Reuss A, Lindemann K, Kurzeder C, Van Nieuwenhuysen E, Marth C, Pietzner K, Ray-Coquard I, Garcia-Duran C, Jonuskiene G, Heitz F, Béllier C, Pérez-Fidalgo JA, El-Balat A, Selle F, Romero I, Wimberger P, Follana P, Pardo B, de Gregorio N, Joly F, Gaba L, Burges A, Fabbro M, Hasenburg A, Fehm T, Schmalfeldt B, Pautier P
doi: 10.1200/JCO-25-01210
Gastrointestinal Cancer
Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): pre-specified interim analysis of a randomized, phase III clinical trial
Ann Oncol
Liu R, Zhao J, Zhang R, Liu B, Liu Y, Li S, Chen Y, Yang H, Liu Z, Li Z, Qin Y, Huang M, Ba Y, Zhang H, Qu Y, Du Y, Deng T, Yang M, Hou X, Liu C, Ning F, Liu YP, Wu X, Xie Y, An Y, Zou K, She L, Xu J
doi: 10.1016/j.annonc.2026.01.006
Skin Cancer
Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial
Eur J Cancer
Demidov L, Samoylenko I, Kharkevich G, Orlova K, Moiseenko V, Utyashev I, Stroyakovskiy D, Kozlov V, Zimina A, Mochalova A, Demidova S, Lyadova M, Kutkovich A, Skopin P, Kovalenko N, Safina S, Volkov V, Semiletova Y, Vaschenko V, Kislov N, Poltoratskiy A, Shumskaya I, Kolomiets S, Sobolev A, Belogortsev I, Odintsova S, Rastogi S, Andabekov T, Penkov K, Semenova A, Obukhov A, Belyakovsky V, Yurchenkov A, Gladkov O, Neve R, Falaleeva N, Poddubskaya E, Vaibhav A, Kirtbaya D, Chapko Y, Smagina M, Fadeeva N, Sorokina I, Mikhailova E, Linkova Y, Zinkina-Orikhan A, Lutskii A, Gabidullin R, Rzaev R, Kryukov F
doi: 10.1016/j.ejca.2025.115674
Lung, Respiratory and Thoracic Cancer
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial
Lancet Oncol
Zhong H, Wang J, Yang R, Luo Y, Zuo W, Zhang W, Xie C, Li Q, Liu Q, Xu X, Wang Q, Yu Y, Chen Y, Yi T, Min X, Shi J, Yang J, Sun H, Chen H, Shi H, Gao J, Shi J, Zhang B, Chu T, Li K, Han B, CAMPASS Investigators
doi: 10.1016/S1470-2045(26)00049-5